Project Grant R01AG082698

Award Date 6/15/24
Completion Date 5/31/29
Dollars Obligated $4.7M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
This federal Project Grant award, provided by the National Institute on Aging under CFDA 93.866 Aging Research, aims to develop explainable and ethical artificial intelligence (AI) models to assist in the diagnosis and prognosis of Alzheimer's disease (AD). The $738,014 award to Emory University, with a period of performance from August 1, 2024 to April 30, 2029, will leverage the institution's expertise in explainable AI, cerebrospinal fluid proteomics, and understanding the role of factors...
The National Institute on Aging (NIA) awarded a $661,016 Project Grant (CFDA 93.866 - Aging Research) to the University of Southern California (USC) to develop a "Federated Deep Learning to Accelerate Alzheimer's Disease Research" platform. This project aims to leverage innovative artificial intelligence (AI) techniques and distributed computing to analyze Alzheimer's disease (AD) biobanks from the U.S., India, Japan, and Europe, totaling over 100,000 MRI and PET scans. The key...
The National Institute on Aging (NIA) awarded a $134,730 Project Grant under the Aging Research program (CFDA 93.866) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop EEG biomarkers (EDSs) for predicting the risk of dementia in older adults. The project aims to investigate complex EEG fluctuations using traditional and novel nonlinear dynamic methods, as well as deep learning techniques, to extract EEG features and construct EDSs. The...
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) provides $4,027,679 to develop a digital cognitive health resource based on the Boston University Alzheimer's Disease Research Center. The project aims to collect and characterize digital cognitive metrics in high-risk and low-risk Alzheimer's disease populations, assess their relationship to vascular risk factors and neuroanatomic measures, and build machine learning models to...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,811,559 to the University of Massachusetts to conduct a study on using wearable devices and AI techniques to develop digital biomarkers for early detection of Alzheimer's disease. The key objectives are to: Deploy consumer wearables for sleep, heart rate, and activity monitoring in a cohort of older adults with elevated genetic risk for Alzheimer's to quantify device accuracy and develop...
This $1,933,556 Project Grant awarded by the National Institute on Aging (NIA) under its Aging Research program (CFDA 93.866) will support research to assess the impact of hospital-based health information technology (hospital-HIT) on healthcare quality and equity for patients with Alzheimer's disease and related dementias (ADRD). The primary awardee, the University of Maryland, College Park, will conduct a ten-year longitudinal study to evaluate how hospital-HIT systems that promote care...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Texas Health Science Center at Houston (UTHealth) aims to develop an interpretable deep learning framework to uncover cognitive resilience factors in Alzheimer's disease (AD). The $897,000 grant, awarded on August 1, 2024, will support research to 1) engineer a deep learning model to identify molecular signatures of resilience groups, and 2) model gene perturbation effects to predict...
This Project Grant award for $353,391.00, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to validate a digital tool called the Personal Learning Curve (PLC) for early detection and sensitive tracking of cognitive changes related to Alzheimer's disease (AD) in a representative sample of older adults at risk for AD and related dementias. The project will recruit 300 participants who have completed the active phase of the U.S. POINTER clinical trial on multi-domain...
This $885,006 project grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a smartphone-based point-of-care diagnostic system to detect Alzheimer's disease (AD) biomarkers, including amyloid-beta, phosphorylated tau, and neurofilament light chain, in blood plasma. The primary recipient, Brigham & Women's Hospital Inc., will leverage microfluidics, nanotechnology, optical sensing, and deep learning to create an affordable, user-friendly test that can...
This $327,500 Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) will fund a 2-year research project by The Johns Hopkins University to develop novel tree-based statistical methods and algorithms for classifying and predicting cognitive decline due to Alzheimer's disease. The project aims to leverage longitudinal biomarker data and risk/protective factors from the Preclinical Alzheimer's Consortium (PAC) to identify high-risk subgroups...

A DEEP LEARNING ALGORITHM TO DETECT SIGNS OF COGNITIVE IMPAIRMENT IN ELECTRONIC HEALTH RECORDS - THE UNDERDIAGNOSIS OF ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (ADRD) HAS SIGNIFICANT CONSEQUENCES, INCLUDING MISSED INTERVENTION OPPORTUNITIES, INCREASED HEALTHCARE COSTS, AND AN UNDERESTIMATION OF THE DISEASE BURDEN. IN ADDITION, CURRENT STUDIES RELYING ON DIAGNOSES AND MEDICATIONS FOR DEFINING COGNITIVE IMPAIRMENT (CI) IN ELECTRONIC HEALTH RECORDS (EHR) ARE LIMITED BY BIASES AND INACCURACIES IN THESE DATA. TO ADDRESS THIS CRITICAL NEED FOR ACCURATE IDENTIFICATION OF COGNITIVE IMPAIRMENT IN EHR, THIS STUDY PROPOSES THE DEVELOPMENT AND EVALUATION OF A DEEP LEARNING ALGORITHM THAT UTILIZES EHR DATA FROM THREE LARGE HEALTHCARE INSTITUTIONS: MASS GENERAL BRIGHAM (MGB), UNIVERSITY OF WISCONSIN-MADISON (UW-MADISON), AND UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO (UTHSCSA). WE SEEK TO LEVERAGE THE WEALTH OF INFORMATION IN EHR INCLUDING CLINICAL NOTES, PATIENT HEALTH HISTORY, AND HEALTH SYSTEM INTERACTIONS THAT OFTEN CONTAIN SIGNS OF COGNITIVE DECLINE. DEEP LEARNING ALGORITHMS CAN LEVERAGE AND LEARN FROM THESE COMPLEX TEXT AND DATA PATTERNS IN EHR. IN THIS PROPOSAL, WE AIM TO DEVELOP AND EVALUATE A DEEP LEARNING ALGORITHM, DECIPHER-AI, TO IMPROVE THE DETECTION OF CI DUE TO UNDERLYING ADRD PATHOPHYSIOLOGY (INCLUDING COGNITIVE CONCERNS, MILD COGNITIVE IMPAIRMENT, AND DEMENTIA). DECIPHER-AI IS A TWO- LEVEL HIERARCHICAL MODEL CONSISTING OF A NOTE-LEVEL NATURAL LANGUAGE PROCESSING (NLP) MODEL THAT PREDICTS THE PROBABILITY OF CI FOR A CLINICAL NOTE AND A PATIENT-LEVEL MODEL THAT COMBINES STRUCTURED DATA AND AGGREGATED NLP OUTPUTS TO PREDICT THE PROBABILITY OF CI FOR A PATIENT. FOR TRAINING AND EVALUATION, WE WILL USE A "SEED" REFERENCE STANDARD SET WITH DETAILED CHART REVIEW AND ADJUDICATION OF COGNITIVE DIAGNOSIS BY AN EXPERT CLINICIAN (N=1,000), AND THEN APPLY ACTIVE LEARNING STRATEGIES TO ITERATIVELY INCREASE SAMPLE SIZE TO N=20,000 (OVERSAMPLING TO INCLUDE 50% FROM MINORITY POPULATIONS). SPECIFICALLY, THE STUDY AIMS TO DEVELOP DECIPHER-AI FOR IDENTIFYING ANY INDICATORS OF COGNITIVE IMPAIRMENT AND DETECT ADRD SUBTYPES (AIM 1); VALIDATE ITS PERFORMANCE AT TWO OTHER HEALTHCARE INSTITUTIONS (AIM 2); AND EXAMINE BIASES AND DIFFERENCES IN PREDICTORS OF CI ACROSS RACE/ETHNIC, SEX, AND SOCIO-ECONOMIC SUBGROUPS (AIM 3). WHILE PREVIOUS RESEARCH HAS DEMONSTRATED SUCCESS IN IDENTIFYING COGNITIVE DYSFUNCTION IN PATIENTS WITHOUT DEMENTIA DIAGNOSES OR MEDICATION, FURTHER EFFORTS ARE REQUIRED TO BUILD INCLUSIVE REFERENCE DATASETS, INTEGRATE STRUCTURED AND UNSTRUCTURED DATA, AND EVALUATE THE ALGORITHM IN DIVERSE HEALTHCARE SETTINGS ACROSS MULTIPLE INSTITUTIONS. CUTTING-EDGE DEEP LEARNING ALGORITHMS HAVE BEEN APPLIED TO MANY REAL-WORLD TASKS BUT IN A LIMITED MANNER TO ADRD. WE ANTICIPATE THAT OUR STATE-OF-THE-ART DEEP LEARNING ALGORITHM WILL MORE EFFICIENTLY AND ACCURATELY DETECT SIGNS OF CI, AND AFTER VALIDATION BE DEPLOYED IN PRIMARY CARE TO SCREEN FOR PATIENTS WITH UNDIAGNOSED COGNITIVE IMPAIRMENT. IN ADDITION, IMPROVED SCREENING OF COGNITIVE IMPAIRMENT IN EHR WILL ENHANCE DEMENTIA RESEARCH STUDIES AND ENABLE LARGE-SCALE PRAGMATIC TRIALS.

Posted 6/10/24, 12:00 AM